ロード中...
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938196/ https://ncbi.nlm.nih.gov/pubmed/31920338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S195552 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|